CMTA Board Welcomes New Directors Bernard Coulie and Kevin Marks

The Charcot-Marie-Tooth Association (CMTA) announced the addition of Bernard Coulie, M.D., Ph.D., and Kevin Marks to its Board of Directors, bringing in their vast experience in corporate, drug development, and compliance. Coulie, the CEO and President of Pliant Therapeutics, has over 20 years in the biopharmaceutical industry and a personal connection to CMT through his son. Kevin Marks comes with a strong legal background in the drug development sector and is currently the Chief Legal Officer at the Parker Institute for Cancer Immunotherapy.

This move aligns with CMTA’s ongoing mission to push forward in finding treatments and ultimately a cure for Charcot-Marie-Tooth disease, a rare condition that affects one in every 2,500 people. Gilles Bouchard, the Chairman of the CMTA Board, expressed enthusiasm for the board’s new additions, underscoring the value of their expertise in advancing treatment development. The association also extends its gratitude to the outgoing board members for their years of service, now transitioning to special advisors.